ERBB3 A232V

CI-VAR-00000086Explore in graph →CIViC 1217

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
ERBB3 A232V	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID9631 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic
ERBB3 A232V	Duligotuzumab + Lapatinib + Pertuzumab + TrastuzumabSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID9630 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
ERBB3 A232V	(functional)	Functional	D	Supports Gain Of Function	2	submitted	EID9629 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic